Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: Possible clinical implications for recombinant human thyrotropin-aided therapy

Thyroid

Volumn 16, Issue 2, 2006, Pages 177-179

  Taïeb, David ^a   Lussato, D ^a   Guedj, E ^a   Roux, F ^a   Mundler, O ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; HUMAN; HYPOTHYROIDISM; INJECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOISOTOPE THERAPY; RISK ASSESSMENT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER;

CELL DIFFERENTIATION; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; SOFTWARE; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645466201     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.177     Document Type: Article

References (11)

1. Mazzaferri EL, Kloos RT 2001 Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
2. Mazzaferri EI, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Hangen BR, Sherman SI, Cooper DS, Braunstein CD, Leo S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the rule of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441.
3. Sawka AM, Thephamongkhol K, Bromvers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676.
4. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43:1482-1488.
5. Barbaro D, Boni C, Meucci C, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115.
6. Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ 1996 Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 37:1962-1964.
7. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A, Brunotte F 2004 Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 45:988-994.
8. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445.
9. M Izumi, T Kubo, M Taura, S Yamashita, I Morimoto, S Ohtakara, S Okamoto, LF Kumagai and S Nagataki 1986 Kinetic study of immunoreactive human thyroglobulin. J Clin Endocrinol Metab 62:410-412.
10. Van Herle AJ, Demeester-Mirkine N, Van Heuverswyn B, Dumont J 1981 The effect of 131I for diagnostic purposes on serum thyroglobulin (hTg) levels in subjects with thyroidal disorders. J Endocrinol Invest 4:107-120.
11. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G 2004 Follow-up and management of differentiated thyroid carcinoma: A European perspective in clinical practice. Eur J Endocrinol 151:539-548.